Results 151 to 160 of about 7,041,329 (294)

Five years on: research, development and changing practice [PDF]

, 2007
Carpentieri, Jon, Howard, Ursula, Mallows, David, Teo, Paula, Vorhaus, John   +4 more
core   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

RESEARCH DEVELOPMENT PRODUCTION [PDF]

Chemical & Engineering News Archive, 1962
openaire   +3 more sources

Liquid metal cooled fast reactor thermal hydraulic research development: A review. [PDF]

Heliyon, 2023
Agbevanu KT, Debrah SK, Arthur EM, Shitsi E.   +3 more
europepmc   +1 more source

Research Developments in International Nutrition [PDF]

American Journal of Public Health and the Nations Health, 1963
openaire   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

A Framework for Assessing the Opportunity for Advanced Research, Development, and Regulatory Approval of Medical Countermeasures: A Component of BARDA's Emerging Infectious Diseases Strategy. [PDF]

J Infect Dis
White RC, Lewis RG, Little JD, Fredericksen BL, Sabourin CL, Lane MC, Loelius SG, Hofmeyer KA, Steele M, Tong X, Johnson RA.   +10 more
europepmc   +1 more source

"Take a walk in someone else's shoes": the role of participatory arts for health research development and training. [PDF]

Res Involv Engagem, 2023
Gillibrand S, Hine P, Conyers R, Gravestock J, Walsh C, McAvoy A, Sanders C.   +6 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Editorial: Advances in bacteriophage research & development with therapeutic applications. [PDF]

Front Cell Infect Microbiol
Gonzalez Moreno M, Alt S, Mercer D.
europepmc   +1 more source